Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 6/20 | 0.39 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14573453 | 1.00 | KMT2A (0.39) | KMT2AMEN1MMP1MMP13SRD5A1 | |
| SCHEMBL3318361 | 0.94 | SRD5A1 (0.45) | KMT2AMEN1MMP1MMP13SRD5A1 | |
| SCHEMBL3319635 | 0.93 | MMP1 (0.40) | KMT2AMEN1MMP1MMP13SRD5A1 | |
| SCHEMBL13361605 | 0.93 | MMP1 (0.40) | KMT2AMEN1MMP1MMP13SRD5A1 | |
| SCHEMBL13333396 | 0.93 | MMP1 (0.40) | KMT2AMEN1MMP1MMP13SRD5A1 | |
| SCHEMBL6424139 | 0.93 | MMP1 (0.44) | KMT2AMEN1MMP1MMP13SRD5A1 | |
| SCHEMBL3323190 | 0.91 | MMP1 (0.42) | MMP1MMP13SRD5A1RORCNAMPT | |
| SCHEMBL13361599 | 0.89 | KMT2A (0.42) | KMT2ASRD5A1MAPTLMNANAMPT | |
| SCHEMBL14607454 | 0.89 | KMT2A (0.42) | KMT2ASRD5A1MAPTLMNANAMPT | |
| SCHEMBL3323158 | 0.86 | KMT2A (0.43) | KMT2ASRD5A1MAPTLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-20050065095-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2005-03-24 | — | — | US | disclosed |
| US-6846825-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065095-A1 | Antibacterial agents | NQO2, DAO, Q6ZSR9 | KMT2A 3765/4885MEN1 2824/4885MMP1 3086/4885 |
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | KMT2A 3725/4885MEN1 2736/4885MMP1 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.